10/511758

DTO1 Rec'd PCT/PTC 1 9 OCT 2004

SEQUENCE LISTING

<110> B.R.A.H.M.S Aktiengesellschaft <120> Verfahren zur Diagnose von Entzündungserkrankungen und Infektionen unter Bestimmung von LASP-1 Immunreaktivität <130> 3677PCT AS <140> <141> <150> 02008840.7 <151> 2002-04-19 <160> 17 <170> PatentIn Ver. 2.1 <210> 1 <211> 261 <212> PRT <213> Homo sapiens <400> 1 Met Asn Pro Asn Cys Ala Arg Cys Gly Lys Ile Val Tyr Pro Thr Glu Lys Val Asn Cys Leu Asp Lys Phe Trp His Lys Ala Cys Phe His Cys Glu Thr Cys Lys Met Thr Leu Asn Met Lys Asn Tyr Lys Gly Tyr Glu Lys Lys Pro Tyr Cys Asn Ala His Tyr Pro Lys Gln Ser Phe Thr Met Val Ala Asp Thr Pro Glu Asn Leu Arg Leu Lys Gln Gln Ser Glu Leu Gln Ser Gln Val Arg Tyr Lys Glu Glu Phe Glu Lys Asn Lys Gly Lys Gly Phe Ser Val Val Ala Asp Thr Pro Glu Leu Gln Arg Ile Lys Lys 105 Thr Gln Asp Gln Ile Ser Asn Ile Lys Tyr His Glu Glu Phe Glu Lys Ser Arg Met Gly Pro Ser Gly Gly Glu Gly Met Glu Pro Glu Arg Arg Asp Ser Gln Asp Gly Ser Ser Tyr Arg Arg Pro Leu Glu Gln Gln 150 155 145 Pro His His Ile Pro Thr Ser Ala Pro Val Tyr Gln Gln Pro Gln Gln Gln Pro Val Ala Gln Ser Tyr Gly Gly Tyr Lys Glu Pro Ala Ala Pro 180 Val Ser Ile Gln Arg Ser Ala Pro Gly Gly Gly Gly Lys Arg Tyr Arg

```
Ala Val Tyr Asp Tyr Ser Ala Ala Asp Glu Asp Glu Val Ser Phe Gln
                        215
Asp Gly Asp Thr Ile Val Asn Val Gln Gln Ile Asp Asp Gly Trp Met
                    230
225
Tyr Gly Thr Val Glu Arg Thr Gly Asp Thr Gly Met Leu Pro Ala Asn
                                     250
Tyr Val Glu Ala Ile
            260
<210> 2
<211> 10
<212> PRT
<213> Homo sapiens
<400> 2
Gln Gln Ser Glu Leu Gln Ser Gln Val Arg
                  5
<210> 3
<211> 9
<212> PRT
<213> Homo sapiens
<400> 3
Ala Cys Phe His Cys Glu Thr Cys Lys
<210> 4
<211> 10
<212> PRT
<213> Homo sapiens
<400> 4
Lys Pro Tyr Cys Asn Ala His Tyr Pro Lys
<210> 5
<211> 10
<212> PRT
<213> Homo sapiens
<400> 5
Val Asn Cys Leu Asp Lys Phe Trp His Lys
<210> 6
<211> 13
<212> PRT
<213> Homo sapiens
```

<400> 6
Gly Phe Ser Val Val Ala Asp Thr Pro Glu Leu Gln Arg
1 5 10

```
<210> 7
<211> 12
<212> PRT
<213> Homo sapiens
<400> 7
Leu Lys Gln Gln Ser Glu Leu Gln Ser Gln Val Arg
                  5
                                       10
<210> 8
<211> 14
<212> PRT
<213> Homo sapiens
<400> 8
Met Gly Pro Ser Gly Gly Glu Gly Met Glu Pro Glu Arg Arg
.<210> 9
<211> 19
<212> PRT
<213> Artificial Sequence
<223> Description of Artificial Sequence: Synthetic
      Peptide
<400> 9
Cys Val Tyr Gln Gln Pro Gln Gln Pro Val Ala Gln Ser Tyr Gly
                                                             15
                                       10
Gly Tyr Lys
<210> 10
<211> 15
<212> PRT
<213> Homo sapiens
Thr Gly Asp Thr Gly Met Leu Pro Ala Asn Tyr Val Glu Ala Ile
<210> 11
<211> 15
<212> PRT
<213> Homo sapiens
<400> 11
Gly Lys Gly Phe Ser Val Val Ala Asp Thr Pro Glu Leu Gln Arg
```

```
<210> 12
<211> 14
<212> PRT
<213> Homo sapiens
<400> 12
Gln Ser Phe Thr Met Val Ala Asp Thr Pro Glu Asn Leu Arg
              . . 5
<210> 13
<211> 18
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      Peptide
<400> 13
Cys Lys Tyr His Glu Glu Phe Glu Lys Ser Arg Met Gly Pro Ser Gly
 1
Gly Glu
<210> 14
<211> 14
<212> PRT
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
      Peptide
<400> 14
Cys Gln Asp Gly Ser Ser Tyr Arg Arg Pro Leu Glu Gln Gln
                                       10
<210> 15
<211> 54
<212> PRT
<213> Artificial Sequence
 <220>
<223> Description of Artificial Sequence: Synthetic
      Peptide
 <400> 15
 Lys Tyr His Glu Glu Phe Glu Lys Ser Arg Met Gly Pro Ser Gly Gly
Glu Gly Gly Gln Asp Gly Ser Ser Tyr Arg Arg Pro Leu Glu Gln
                                                        30
                                   25
 Gln Gly Gly Gly Val Tyr Gln Gln Pro Gln Gln Gln Pro Val Ala Gln
 Ser Tyr Gly Gly Tyr Lys
      50
```

<210> 16 <211> 323 <212> PRT <213> Homo sapiens

<400> 16 Met Asn Pro Asn Cys Ala Arg Cys Gly Lys Ile Val Tyr Pro Thr Glu 10 Lys Val Asn Cys Leu Asp Lys Phe Trp His Lys Ala Cys Phe His Cys Glu Thr Cys Lys Met Thr Leu Asn Met Lys Asn Tyr Lys Gly Tyr Glu Lys Lys Pro Tyr Cys Asn Ala His Tyr Pro Lys Gln Ser Phe Thr Met Val Ala Asp Thr Pro Glu Asn Leu Arg Leu Lys Gln Gln Ser Glu Leu Gln Ser Gln Val Arg Tyr Lys Glu Glu Phe Glu Lys Asn Lys Gly Lys Gly Phe Ser Val Val Ala Asp Thr Pro Glu Leu Gln Arg Ile Lys Lys Thr Gln Asp Gln Ile Ser Asn Ile Lys Tyr His Glu Glu Phe Glu Lys Ser Arg Met Gly Pro Ser Gly Gly Glu Gly Met Glu Pro Glu Arg Arg 135 Asp Ser Gln Asp Gly Ser Ser Tyr Arg Arg Pro Leu Glu Gln Gln Pro His His Ile Pro Thr Ser Ala Pro Val Tyr Gln Gln Pro Gln Gln Gln Pro Val Ala Gln Ser Tyr Gly Gly Tyr Lys Glu Pro Ala Ala Pro 185 Val Ser Ile Gln Arg Ser Ala Pro Ile Cys Leu Gln His Ile Pro Arg 200 His Arg Ile Arg Pro Gly Arg Asp Pro Ser Ile Leu Gln Cys Leu Cys Phe Leu Lys Pro Ala Thr Ala Cys Asp Ser Tyr Pro Ser Ser Phe 230 Phe Cys Gln Leu Lys Pro Ser Ser Ala Thr Ser Ala Gly Ser Leu Leu Trp Gln Ala Ser Pro Leu Ile Asp Phe Leu Val Phe Ser Leu Asp Gly 260 Thr Gly Met Gly Leu Ser Gly Gly Gly Arg Gly Pro Trp Gly Arg Ala Gly Met Gly Asp Leu Leu Ala Cys Gly Pro His Leu Pro Leu Cys Ser Leu Pro Ser His Pro Pro Ala Gln Leu Leu Thr Tyr Pro His Ile Pro 305 310

Gly Leu Gly

<210> 17

<211> 19 <212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Synthetic Peptide

<400> 17

Cys Val Tyr Gln Gln Pro Gln Gln Pro Val Ala Gln Ser Tyr Gly 15

Gly Tyr Lys